Cancer

breast cancer

Regulation

downregulation

Reporting

RNA was extracted reverse transcribed and subjected to microarray analysis n = 10 Luminal A-like; n = 10 Control. Microarray analysis identified 76 differentially expressed miRNAs. ANN revealed 10 miRNAs for further analysis miR-19b miR-29a miR-93 miR-181a miR-182 miR-223 miR-301a miR-423-5p miR-486-5 and miR-652. The biomarker potential of 4 miRNAs miR-29a miR-181a miR-223 and miR-652 was confirmed by RQ-PCR with significantly reduced expression in blood of women with Luminal A-like breast tumors compared to healthy controls p = 0.001 0.004 0.009 and 0.004 respectively. Binary logistic regression confirmed that combination of 3 of these miRNAs miR-29a miR-181a and miR-652 could reliably differentiate between cancers and controls with an AUC of 0.80

Pubmed

24498016

Method

Microarray

Cancer

esophageal cancer

Regulation

deregulation

Reporting

Differentially-expressed miRNAs were analyzed using real-time quantitative reverse transcription polymerase chain reaction. The most noticeably up-regulated miRNAs included hsa-miR-31 hsa-miR- 196b hsa-miR-652 hsa-miR-125a-5p hsa-miR-146b hsa-miR-200c hsa-miR-23b hsa-miR-29a hsa-miR-186 hsa-miR-205 hsa-miR-376a hsa-miR-410 hsa-miR-532-3p and hsa-miR-598 whereas the most significantly- downregulated miRNAs were hsa-let-7e hsa-miR-130b and hsa-miR-103

Pubmed

23534712

Method

Reverse transcription PCR

Cancer

gastric cancer

Regulation

upregulation

Reporting

Plasma samples from 3 independent groups comprise 123 gastric cancer patients and 111 healthy controls for miRNA profiling from microarray screening. Microarray data showed that 25 miRNAs were upregulated in gastric cancer patients and 6 highly expressed miRNAs miR-18a miR-140-5p miR-199a-3p miR-627 miR-629 and miR-652 were selected for validation. In an independent validation set levels of miR-627 miR-629 and miR-652 were significantly higher in gastric cancer patients than healthy controls P <0.0001

Pubmed

26607322

Method

Microarray

Cancer

lung squamous cell cancer

Regulation

upregulation

Reporting

MiR 652 3p is upregulated in non small cell lung cancer and promotes proliferation and metastasis by directly targeting Lgl1. Our previous study found that miR-652-3p is markedly upregulated in the serum of patients with NSCLC and suggesting that miR-652-3p is a potential biomarker for the early diagnosis of NSCLC. In this study we detected the expression of miR-652-3p in NSCLC tumor tissues and cell lines and investigated the effect of miR-652-3p on the proliferation and metastasis of NSCLC cells. Our results showed that the expression of miR-652-3p was significantly upregulated in tumor tissues of 50 patients with NSCLC and it was significantly higher in patients with positive lymph node metastasis advanced TNM stage and poor prognosis. Moreover the lethal2 giant larvae 1 Lgl1 was identified as a direct and functional target of miR-652-3p. Overexpression of Lgl1 partially attenuated the function of miR-652-3p. Collectively these results revealed that miR-652-3p execute a tumor-promoter function in NSCLC through direct binding and regulating the expression of Lgl1

Pubmed

26934648

Method